219A
Heartseed Inc.
Ｈｅａｒｔｓｅｅｄ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Notes
- Fiscal period changeDec 2025 / 14-month fiscal period
Key metrics
Revenue(thousand JPY)
Oct 2024
873,610
Dec 2025
14-month fiscal period
3,026,500
Operating profit(thousand JPY)
Oct 2024
-1,038,802
Dec 2025
14-month fiscal period
272,156
Operating profit margin(%)
Oct 2024
-118.91
Dec 2025
14-month fiscal period
8.99
Profit before tax(thousand JPY)
Oct 2024
-818,581
Dec 2025
14-month fiscal period
288,985
Profit(thousand JPY)
Oct 2024
-812,725
Dec 2025
14-month fiscal period
190,608
Total assets(thousand JPY)
Oct 2024
7,067,594
Dec 2025
14-month fiscal period
7,675,749
Cash and cash equivalents(thousand JPY)
Oct 2024
5,297,166
Dec 2025
14-month fiscal period
6,836,009
Cash flows from operating activities(thousand JPY)
Oct 2024
-1,343,039
Dec 2025
14-month fiscal period
1,080,526
Cash flows from investing activities(thousand JPY)
Oct 2024
-67,130
Dec 2025
14-month fiscal period
72,636
Cash flows from financing activities(thousand JPY)
Oct 2024
2,118,845
Dec 2025
14-month fiscal period
375,762
Return on equity(%)
Oct 2024
-
Dec 2025
14-month fiscal period
2.76
Equity ratio(%)
Oct 2024
93.54
Dec 2025
14-month fiscal period
93.67
Earnings per share(JPY per share)
Oct 2024
-49.43
Dec 2025
14-month fiscal period
8.44
Net assets per share(JPY per share)
Oct 2024
297.44
Dec 2025
14-month fiscal period
314.56
Dividend per share(-)
Oct 2024
-
Dec 2025
14-month fiscal period
-
Payout ratio(-)
Oct 2024
-
Dec 2025
14-month fiscal period
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.